← Eichor
Study identifier: NCT06736288 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Post Authorization Efficacy and Safety Study (PAES) to Confirm and Collect More Clinical Data of Buccalin® Tablets In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIs).

Condition: Respiratory Infection · Lower Respiratory Tract Infection (LRTI)  ·  Sponsor: Laboratorio Farmaceutico SIT srl

PhasePhase 4
Planned participants240
Who can joinAll sexes, 18 Years to 99 Years
Healthy volunteersNo

About this study

The goal of this clinical trial is to assess if BUCCALIN® works In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIS). It will also evaluate the safety of BUCCALIN®. The primary aim is to reduce the number of infection episodes in the treatment period (12 months) in the BUCCALIN® group versus the Placebo group. Patients diagnosed with RLRTIS will be screened for enrolment. Patients will be requested to provide informed consent before the start of the study related assessments. Eligible patients who meet the study inclusion and exclusion criteria will be randomized with a 1:1 ratio allocation to the 2 treatment groups. Researchers will compare BUCCALIN® (gastro-resistant tablets) to a placebo (gastro-resistant tablets containing only excipients) to treat RLRTIS. Patients who participate in the study will perform several study visits divided as reported below: * Run-in phase (12 months): patients will not receive any treatment. This phase is designed to increase adherence to the study and reduce loss to follow-up in the clinical trial. During this phase, patients should experience ≥ 2 episodes of RTIs to be eligible for the Treatment period. * Treatment period (12 months): patients will receive BUCCALIN® or Placebo treatment for 12 consecutive months (3 days per month, posology as per authorized SmPC). * Follow-up period (12 months): patients will not receive any treatment. This phase is designed to observe how patients respond to treatments.

This description comes directly from the study's public registry record.

Talk to the study team

Silvana Lonetti  ·  +39 0384 8071  ·  s.lonetti@sit-farmaceutici.com

Always discuss trial participation with your own doctor first.

Locations (10)

AOU Ss. Antonio E Biagio E C.ArrigoAlessandria, ItalyActive Not Recruiting
AOU Policlinico G. Rodolico-San MarcoCatania, ItalyActive Not Recruiting
ASST Fatebenefratelli SaccoMilan, ItalyActive Not Recruiting
ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyActive Not Recruiting
ASST Santi Paolo e CarloMilan, ItalyRecruiting
Fondazione IRCCS Ca Granda Ospedale Maggiore PoliclinicoMilan, ItalyActive Not Recruiting
Humanitas Mirasole S.p.AMilan, ItalyActive Not Recruiting
AOU Policlinico Tor VergataRoma, ItalyActive Not Recruiting
AOU di SassariSassari, ItalyRecruiting
University clinic for infectious diseases and febrile conditions, Medical Faculty, Ss Cyril and Methodius UniversitySkopje, North MacedoniaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06736288